Filter Results:
(1,244)
Show Results For
- All HBS Web
(1,244)
- People (5)
- News (171)
- Research (928)
- Events (6)
- Multimedia (12)
- Faculty Publications (756)
Show Results For
- All HBS Web
(1,244)
- People (5)
- News (171)
- Research (928)
- Events (6)
- Multimedia (12)
- Faculty Publications (756)
- May 2011 (Revised July 2012)
- Exercise
Remicade/Simponi: Confidential Instructions for Merck
By: Guhan Subramanian and Rhea Ghosh
This two-party negotiation exercise features a real-life dispute between Merck and Johnson & Johnson regarding European distribution rights to two highly lucrative drugs. View Details
Keywords: Price; Rights; Agreements and Arrangements; Negotiation Deal; Problems and Challenges; Risk and Uncertainty; Pharmaceutical Industry
Subramanian, Guhan, and Rhea Ghosh. "Remicade/Simponi: Confidential Instructions for Merck." Harvard Business School Exercise 911-044, May 2011. (Revised July 2012.)
- December 2010
- Teaching Note
Organization and Strategy at Millennium (TN) (A) & (B)
By: Julie M. Wulf
Teaching Note for 710-415 and 710-418. View Details
- July 2009 (Revised May 2010)
- Case
Pfizer: Letter from the Chairman (A)
By: Robert L. Simons and Natalie Kindred
This case explores maximizing shareholder value as a goal in executive decision making. Over a period of nine years, three different Pfizer CEOs make critical decisions intended to increase shareholder value. But the results are disappointing. To allow students to... View Details
Keywords: Decision Choices and Conditions; Corporate Accountability; Corporate Governance; Annual Reports; Business and Shareholder Relations; Value Creation; Pharmaceutical Industry; United States
Simons, Robert L., and Natalie Kindred. "Pfizer: Letter from the Chairman (A)." Harvard Business School Case 110-003, July 2009. (Revised May 2010.)
- April 2009
- Teaching Note
Amylin Pharmaceuticals: Diabetes and Beyond (TN)
By: Richard G. Hamermesh and Rachel Gordon
Teaching Note for [809011]. View Details
- April 2009
- Supplement
Merck: Managing Vioxx (G)
By: Robert L. Simons and Natalie Kindred
Keywords: Decision Choices and Conditions; Leadership; Customer Focus and Relationships; Pharmaceutical Industry
Simons, Robert L., and Natalie Kindred. "Merck: Managing Vioxx (G)." Harvard Business School Supplement 109-086, April 2009.
- April 2009 (Revised April 2010)
- Supplement
Merck: Managing Vioxx (F)
By: Robert L. Simons and Natalie Kindred
Simons, Robert L., and Natalie Kindred. "Merck: Managing Vioxx (F)." Harvard Business School Supplement 109-085, April 2009. (Revised April 2010.)
- April 2009
- Supplement
Merck: Managing Vioxx (D)
By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred
Keywords: Pharmaceutical Industry
Simons, Robert L., Kathryn Rosenberg, and Natalie Kindred. "Merck: Managing Vioxx (D)." Harvard Business School Supplement 109-083, April 2009.
- April 2009
- Supplement
Merck: Managing Vioxx (C)
By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred
Keywords: Pharmaceutical Industry
Simons, Robert L., Kathryn Rosenberg, and Natalie Kindred. "Merck: Managing Vioxx (C)." Harvard Business School Supplement 109-082, April 2009.
- April 2009 (Revised April 2010)
- Supplement
Merck: Managing Vioxx (B)
By: Robert L. Simons, Kathryn Rosenberg and Natalie Kindred
Simons, Robert L., Kathryn Rosenberg, and Natalie Kindred. "Merck: Managing Vioxx (B)." Harvard Business School Supplement 109-081, April 2009. (Revised April 2010.)
- 2008
- Case
Eli Lilly: Recreating Drug Discovery for the 21st Century
By: Rebecca Henderson and C. Reavis
- May 2006
- Teaching Note
WuXi PharmaTech (TN)
By: Richard G. Hamermesh and Erin Seefeld
Keywords: Pharmaceutical Industry
- March 2006 (Revised February 2009)
- Teaching Note
Molecular Insight Pharmaceuticals, Inc. (TN)
By: Richard G. Hamermesh and Erin Seefeld
Teaching Note to (805-067). View Details
Keywords: Pharmaceutical Industry
- February 2005 (Revised March 2005)
- Teaching Note
Product Team Cialis: Getting Ready to Market (TN)
By: Elie Ofek
Teaching Note to (9-505-038). View Details
- February 2005 (Revised April 2006)
- Case
Rx Depot: Importing Drugs from Canada
By: Debora L. Spar
In 2002, a handful of entrepreneurs began to ship drugs from Canada into the United States, taking advantage of regulatory and price differentials across the neighboring countries. Using the Internet and a low-cost network of Canadian pharmacies, firms like Rx Depot... View Details
Keywords: Courts and Trials; Entrepreneurship; Intellectual Property; Laws and Statutes; Pharmaceutical Industry; Canada; United States
Spar, Debora L., and Adam Day. "Rx Depot: Importing Drugs from Canada." Harvard Business School Case 705-010, February 2005. (Revised April 2006.)
- 2003
- Chapter
La tragédie de la thalidomide: affaires judiciaries et résponses législatives, 1959-1971
By: Arthur A. Daemmrich
- May 2002 (Revised October 2005)
- Case
Marketing Antidepressants: Prozac and Paxil
By: Youngme E. Moon and Kerry Herman
Describes the marketing of Prozac and Paxil, two of the best-selling mental health drugs in history. Set in 2001, several months before the expiration of Prozac's patent, Eli Lilly (Prozac's manufacturer) and GlaxoSmithKline (Paxil's manufacturer) must decide how to... View Details
Keywords: Patents; Product Positioning; Competition; Ethics; Value; Health Care and Treatment; Brands and Branding; Pharmaceutical Industry; United States
Moon, Youngme E., and Kerry Herman. "Marketing Antidepressants: Prozac and Paxil." Harvard Business School Case 502-055, May 2002. (Revised October 2005.)
- April 2002
- Supplement
Grey Warner, Merck Latin America
By: Michael Beer
Grey Warner, the vice president of Merck's Latin America region, discusses the challenges raised in the case and the lessons learned. View Details
Keywords: Strategic Planning; Values and Beliefs; Change Management; Problems and Challenges; Management Teams; Pharmaceutical Industry; Latin America
Beer, Michael. "Grey Warner, Merck Latin America." Harvard Business School Video Supplement 402-801, April 2002.
- February 2001 (Revised July 2006)
- Case
Discovering the Future: R&D Strategy at Merck
By: Gary P. Pisano
Given explosive growth in technologies for drug discovery, how does Merck remain competitive in an industry that is fragmented and continues to consolidate? View Details
Pisano, Gary P. "Discovering the Future: R&D Strategy at Merck." Harvard Business School Case 601-086, February 2001. (Revised July 2006.)
- May 1987
- Teaching Note
Eli Lilly and Co. (A) and (B), Teaching Note
By: William J. Bruns Jr.
Keywords: Pharmaceutical Industry
- June 1999 (Revised October 1999)
- Case
Eli Lilly, 1998 (A): Strategic Challenges
By: Michael Y. Yoshino and Thomas W. Malnight
Deals with key strategic challenges facing Eli Lilly, a highly successful U.S.-based drug company. View Details
Yoshino, Michael Y., and Thomas W. Malnight. "Eli Lilly, 1998 (A): Strategic Challenges." Harvard Business School Case 399-173, June 1999. (Revised October 1999.)